Skip to main content

INSM Insmed Incorporated

Healthcare

109.31 -3.27 -2.90% Close 11/2
Since 2024-12-02 +55.5%
Open
112.68
High
113.05
Low
109.22
Prev close
112.58
Volume
4.2M
Amplitude
3.40%
P/B
34.0
Revenue YoY (TTM)
+240.0%
52W 90.39 212.75

Is Insmed Incorporated a buy? Fundamentals and valuation first

As of 2026-10-30

Growth: Good, Risk / liquidity: Good; Valuation: Expensive, Quality: Weak.

Valuation Expensive Free-cash-flow yield is Average; Price / book is Expensive.
TTM P/E -39.92 N/A
Price / book 34.01 98th percentile Expensive
Free-cash-flow yield (%) -2.66 36th percentile Average
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Weak All 3 indicators are Lagging.
ROE, TTM (%) -83.39 13th percentile Lagging
Operating margin, TTM (%) -35.59 19th percentile Lagging
FCF margin, TTM (%) -43.27 19th percentile Lagging
Quality Factor Investing: A US Quality Value Backtest
Growth Good Revenue growth, TTM YoY is Top, but Diluted EPS growth, TTM YoY is Average.
Revenue growth, TTM YoY (%) 239.97 95th percentile Top
Diluted EPS growth, TTM YoY (%) -54.44 34th percentile Average
Momentum Neutral All 2 indicators are Average.
60-day return (%) -15.07 34th percentile Average
240-day return (%) -41.73 21th percentile Average
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Good 20-day dollar volume is Top, but 60-day annualized volatility is Average.
20-day dollar volume 377,578,549 96th percentile Top
60-day annualized volatility (%) 48.17 54th percentile Average
Factor Investing Explained: 10 Classic Factors in US Stocks

Insmed Incorporated (INSM) today

1 quant signals active · As of 2026-10-30

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

FinLab Studio

From Insmed Incorporated to every stock like it

AI finds several complementary traits of Insmed Incorporated across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like Insmed Incorporated

Insmed Incorporated (INSM) peers and tracking

Watchlist

This page refreshes daily after the close. Add Insmed Incorporated to your watchlist to track signal changes on your next visit.

Insmed Incorporated (INSM) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Filed revenue acceleration

Active · now 239.97%

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

13 historical occurrences (since 2022-02-17)

Average forward return after Filed revenue acceleration

20-day: Win 58.3%, Sample 12, Median +1.73%, Excess +1.26%, Beat mkt rate 58.3%

60-day: Win 33.3%, Sample 12, Median -8.8%, Excess +1.15%, Beat mkt rate 33.3%

120-day: Win 54.5%, Sample 11, Median +3.83%, Excess +22.92%, Beat mkt rate 45.5%

120 days after: historical avg +27.83%

20-day +2.68%
60-day +3.93%
120-day +27.83%
20-day
60-day
120-day
Win
58.3%
33.3%
54.5%
Sample
12
12
11
Median
+1.73%
-8.8%
+3.83%
Excess
+1.26%
+1.15%
+22.92%
Beat mkt rate
58.3%
33.3%
45.5%

Over 11 occurrences, 120-day forward avg gained 27.83%, beat the market by 22.92 pts; win rate 54.5%.

More history: Market-wide momentum baseline, Signals not active now

Market-wide momentum baseline

Across 99,493 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.42%, a 58.4% positive-return rate, and +3.08 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

22 times historically; 60-day forward avg +1.77%, win rate 50%, beating the market by -1.77 pts on average.

Top-quintile 6-month momentum

Pending

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

Momentum Trading Strategy: A 12-1 Momentum Backtest

21 times historically; 60-day forward avg +11.49%, win rate 57.1%, beating the market by +6.04 pts on average.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

PEAD: Post-Earnings Announcement Drift Backtest

7 times historically; 60-day forward avg +23.11%, win rate 20%, beating the market by +23.73 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.